
Loading, please wait...

Loading, please wait...

Researchers recently conducted a significant trial comparing different targets for Meige syndrome DBS. This randomized, controlled, double-blind multicenter study evaluated the safety and efficacy of the globus pallidus internus (GPi) and the subthalamic nucleus (STN). Consequently, clinicians now have high-quality evidence to guide surgical decisions for this challenging movement disorder. Both targets demonstrated comparable improvements in motor symptoms and patient quality of life.
The 62 participants received either GPi or STN stimulation. After a 12-month follow-up, both groups achieved nearly 60% improvement in motor function scores. Furthermore, mood and cognitive stability remained consistent across both cohorts. However, the STN-DBS group required significantly less total electrical energy than the GPi group. Notably, researchers used lead-mapping technology to identify precise stimulation "sweet spots." For GPi-DBS, the posterolateral dorsal pallidum offered the best outcomes. In contrast, the dorsal STN proved to be the ideal site for the subthalamic target.
Identifying which patients respond best to therapy is vital for clinical success. The study found that preoperative impairment in speech and swallowing negatively impacts efficacy. Specifically, patients with higher disability scores in these areas experienced less overall benefit from surgery. Therefore, clinicians should carefully screen these subscores during preoperative assessments. This trial provides a refined roadmap for functional neurosurgeons treating refractory cases of Meige syndrome.
Both the GPi and STN targets provide similar motor improvements and safety profiles. However, STN-DBS typically requires lower electrical energy settings to achieve these results.
The trial showed that Meige syndrome DBS significantly enhances quality of life, mood, and motor control, with results remaining stable for at least one year post-surgery.
Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.
References
Wu Y et al. Pallidus internus versus subthalamic nucleus deep brain stimulation for Meige syndrome: a randomized, controlled, double-blind multicenter trial. J Neurosurg. 2026 Feb 20. doi: 10.3171/2025.9.JNS251188. PMID: 41719550.
Guizhi Wu et al. Globus pallidus internus versus subthalamic nucleus deep brain stimulation for Meige syndrome: a retrospective study on short- and long-term efficacy. J Neurosurg. 2026 Feb 6. doi: 10.3171/2025.9.JNS251420. PMID: 41650451.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Randomized multicenter trial finds GPi and STN DBS equally effective for Meige syndrome, with specific stimulation sweet spots identified for each target....
5 months ago

Cutaneous leishmaniasis in HIV-coinfected patients presents unique diagnostic and therapeutic challenges, often manifesting as disseminated disease. Effective care requires systemic antileishmanial regimens and immune recovery.
Today

A comprehensive data mining study reveals how online communities discuss cannabis use during pregnancy. Learn why nonexpert advice dominates digital platforms, the maternal-fetal risks of cannabinoids, and how clinicians can proactively address patient queries with evidence-based counseling.
Today

A new temporal validation study demonstrates that machine learning models analyzing free-text EMS dispatch narratives significantly improve prehospital risk stratification for suspected cardiopulmonary emergencies, boosting predictive accuracy over traditional structured triage data alone.
Today

A comprehensive analysis of 2,764 trauma registry patients reveals that occupant ejection during rollover crashes increases mortality fourfold. Nonuse of seatbelts escalates ejection risk tenfold, highlighting the urgent need for strict restraint compliance and targeted road-safety interventions.
Today

Diabetic kidney disease remains a major cause of renal failure despite renin-angiotensin system blockade. Learn how combining SGLT2 inhibitors, nonsteroidal MRAs, GLP-1 receptor agonists, and novel aldosterone synthase or endothelin inhibitors addresses residual cardiorenal risk.
Today